These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33054092)

  • 1. Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine.
    Li H; Wang Y; Pang X; Xie C; Deeg JH; Wang H; Wan T; Wu J; Guan F; Li X
    Haematologica; 2020 Oct; 105(10):e502. PubMed ID: 33054092
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions.
    Short NJ; Kantarjian H
    Am J Hematol; 2022 Dec; 97(12):1616-1626. PubMed ID: 35871436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical update on hypomethylating agents.
    Duchmann M; Itzykson R
    Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes.
    Straube J; Lane SW; Vu T
    Bioessays; 2021 Oct; 43(10):e2100125. PubMed ID: 34463368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
    Feld J; Tremblay D; Navada SC; Silverman LR
    Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs.
    Short NJ; Dombret H; Adès L; Kantarjian H
    Cancer J; 2022 Jan-Feb 01; 28(1):29-36. PubMed ID: 35072371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
    Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
    [No Abstract]   [Full Text] [Related]  

  • 9. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
    Ravandi F; Issa JP; Garcia-Manero G; O'Brien S; Pierce S; Shan J; Borthakur G; Verstovsek S; Faderl S; Cortes J; Kantarjian H
    Cancer; 2009 Dec; 115(24):5746-51. PubMed ID: 19795507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
    Wang H; Li Y; Lv N; Li Y; Wang L; Yu L
    Ann Hematol; 2018 Nov; 97(11):2025-2038. PubMed ID: 30084010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors.
    Ye C; Jiang N; Zheng J; Zhang S; Zhang J; Zhou J
    Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189066. PubMed ID: 38163523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
    Müller-Thomas C; Rudelius M; Rondak IC; Haferlach T; Schanz J; Huberle C; Schmidt B; Blaser R; Kremer M; Peschel C; Germing U; Platzbecker U; Götze K
    Haematologica; 2014 Oct; 99(10):e179-81. PubMed ID: 24972774
    [No Abstract]   [Full Text] [Related]  

  • 15. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
    Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological effects of hypomethylating agents.
    Lindblad KE; Goswami M; Hourigan CS; Oetjen KA
    Expert Rev Hematol; 2017 Aug; 10(8):745-752. PubMed ID: 28644756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.
    Gruszczynska A; Maiti A; Miller CA; Ramakrishnan SM; Link DC; Uy GL; Petti AA; Hayes K; DiNardo CD; Ravandi F; Ley TJ; Spencer DH; Gao F; Konopleva MY; Welch JS
    Haematologica; 2024 Aug; 109(8):2653-2659. PubMed ID: 38618679
    [No Abstract]   [Full Text] [Related]  

  • 19. [The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients].
    Ai H; Wei XD; Yin QS; Wang P; Mi RH; Yuan FF; Chen L; Song YP
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):606-609. PubMed ID: 28789495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
    Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.